The Meaning, Measurement and Modification of Hypoxia in the Laboratory and the Clinic

Clinical Oncology

Volumn 26, Issue 5, 2014, Pages 277-288

  Hammond, E M ^a   Asselin, M C ^b   Forster, D ^b   O'Connor, J P B ^b   Senra, J M ^a   Williams, K J ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Hypoxia; Hypoxia activated prodrugs; Imaging; Oxygen; Radiation

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BRCA1 PROTEIN; CARBONATE DEHYDRATASE IX; CHECKPOINT KINASE 1; ERYTHROPOIETIN; FLUORO 2 (2 NITRO 1H IMIDAZOLE 1 YL) N (2,2,3,3,3 PENTA FLUOROPROPYL) ACETAMIDE F 18; FLUORO 2 [4 [(2 NITRO 1H IMIDAZOLE 1 YL)METHYL] 1H 1,2,3 TRIAZOL 1 YL]PROPAN 1 OL; FLUOROAZOMYCIN ARABINOFURANOSIDE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; FLUOROMISONID AZOLE F 18; GADOLINIUM; GLUCOSE TRANSPORTER 1; HISTONE H2AX; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR 3ALPHA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITROIMIDAZOLE DERIVATIVE; OSTEOPONTIN; PIMONIDAZOLE; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAD51 PROTEIN; TIRAPAZAMINE; TRACER; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN A; ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1; OXYGEN; PRODRUG;

ARTICLE; BOLD SIGNAL; CANCER PROGNOSIS; CANCER RESISTANCE; CONTRAST ENHANCEMENT; DNA DAMAGE; DNA REPAIR; GENE SILENCING; HEAD AND NECK CANCER; HOMOLOGOUS RECOMBINATION; HUMAN; HYPOXIA; HYPOXIC CELL; IMMUNOHISTOCHEMISTRY; NEEDLE ELECTRODE; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN CONCENTRATION; OXYGEN TENSION; OXYGENATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA TRANSLATION; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR CELL; TUMOR HYPOXIA; UNFOLDED PROTEIN RESPONSE; ANIMAL; CELL HYPOXIA; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PHYSIOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MAGNETIC RESONANCE IMAGING; NEOPLASMS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; PRODRUGS; SIGNAL TRANSDUCTION;

EID: 84898032722     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.02.002     Document Type: Article

References (123)

1. Hall E.J., Giaccia A.J. Radiobiology for the radiologist 2006, Lippincott Williams & Wilkins, Philadelphia, USA. 6th ed.
2. Carreau A., El Hafny-Rahbi B., Matejuk A., Grillon C., Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. JCell Mol Med 2011, 15(6):1239-1253.
3. Dings J., Meixensberger J., Jager A., Roosen K. Clinical experience with 118 brain tissue oxygen partial pressure catheter probes. Neurosurgery 1998, 43(5):1082-1095.
4. Le Q.T., Chen E., Salim A., et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006, 12(5):1507-1514.
5. Brooks A.J., Eastwood J., Beckingham I.J., Girling K.J. Liver tissue partial pressure of oxygen and carbon dioxide during partial hepatectomy. Br J Anaesth 2004, 92(5):735-737.
6. Muller M., Padberg W., Schindler E., et al. Renocortical tissue oxygen pressure measurements in patients undergoing living donor kidney transplantation. Anesth Analg 1998, 87(2):474-476.
7. Boekstegers P., Riessen R., Seyde W. Oxygen partial pressure distribution within skeletal muscle: indicator of whole body oxygen delivery in patients?. Adv Exp Med Biol 1990, 277:507-514.
8. Harrison J.S., Rameshwar P., Chang V., Bandari P. Oxygen saturation in the bone marrow of healthy volunteers. Blood 2002, 99(1):394.
9. Wang W., Winlove C.P., Michel C.C. Oxygen partial pressure in outer layers of skin of human finger nail folds. JPhysiol 2003, 549(Pt 3):855-863.
10. Thermann M., Jostarndt L., Eberhard F., Richter H., Sass W. Oxygen supply of the human small intestine in mechanical ileus. Langenbecks Arch Chir 1985, 363(3):179-184.
11. Gray L.H., Conger A.D., Ebert M., Hornsey S., Scott O.C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953, 26(312):638-648.
12. Thomlinson R.H., Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955, 9(4):539-549.
13. Begg A.C., Stewart F.A., Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011, 11(4):239-253.
14. Cosse J.P., Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008, 8(7):790-797.
15. Barker H.E., Cox T.R., Erler J.T. The rationale for targeting the LOX family in cancer. Nat Rev Cancer 2012, 12(8):540-552.
16. Fokas E., McKenna W.G., Muschel R.J. The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies. Cancer Metastasis Rev 2012, 31(3-4):823-842.
17. Brown J.M., Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998, 58(7):1408-1416.
18. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77(1):18-24.
19. Vaupel P., Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004, 9(Suppl.5):4-9.
20. Brown J.M., Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4(6):437-447.
21. Delaney G., Jacob S., Featherstone C., Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005, 104(6):1129-1137.
22. Brahimi-Horn M.C., Pouyssegur J. HIF at a glance. JCell Sci 2009, 122(Pt 8):1055-1057.
23. Keith B., Johnson R.S., Simon M.C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012, 12(1):9-22.
24. Schofield C.J., Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004, 5(5):343-354.
25. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3(10):721-732.
26. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011, 11(6):393-410.
27. Bristow R.G., Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8(3):180-192.
28. Kumareswaran R., Ludkovski O., Meng A., Sykes J., Pintilie M., Bristow R.G. Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability. JCell Sci 2012, 125(Pt 1):189-199.
29. Bindra R.S., Gibson S.L., Meng A., et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 2005, 65(24):11597-11604.
30. Koshiji M., To K.K., Hammer S., et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 2005, 17(6):793-803.
31. Crosby M.E., Kulshreshtha R., Ivan M., Glazer P.M. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 2009, 69(3):1221-1229.
32. Ramaekers C.H.M.A., van den Beucken T., Meng A., et al. Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. Radiother Oncol 2011, 101(1):190-197.
33. Chen H., Yan Y., Davidson T.L., Shinkai Y., Costa M. Hypoxic stress induces dimethylated histone H3 lysine 9 through histone methyltransferase G9a in mammalian cells. Cancer Res 2006, 66(18):9009-9016.
34. Bindra R.S., Glazer P.M. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 2007, 26(14):2048-2057.
35. Koumenis C., Wouters B.G. "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. Mol Cancer Res 2006, 4(7):423-436.
36. Rzymski T., Harris A.L. The unfolded protein response and integrated stress response to anoxia. Clin Cancer Res 2007, 13(9):2537-2540.
37. Pires I.M., Olcina M.M., Anbalagan S., et al. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. Br J Cancer 2012, 107(2):291-299.
38. Olcina M., Lecane P.S., Hammond E.M. Targeting hypoxic cells through the DNA damage response. Clin Cancer Res 2010, 16(23):5624-5629.
39. Economopoulou M., Langer H.F., Celeste A., et al. Histone H2AX is integral to hypoxia-driven neovascularization. Nat Med 2009, 15(5):553-558.
40. Rankin E.B., Giaccia A.J., Hammond E.M. Bringing H2AX into the angiogenesis family. Cancer Cell 2009, 15(6):459-461.
41. Papandreou I., Krishna C., Kaper F., Cai D., Giaccia A.J., Denko N.C. Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res 2005, 65(8):3171-3178.
42. Hammond E.M., Kaufmann M.R., Giaccia A.J. Oxygen sensing and the DNA-damage response. Curr Opin Cell Biol 2007, 19(6):680-684.
43. O'Brien E.M., Senra J.M., Anbalagan S., Hill M.A., Hammond E.M. Impact of Wee1 inhibition on the hypoxia-induced DNA damage response. Tumor Microenviron Ther 2013, 1:37-45.
44. Pires I.M., Bencokova Z., Milani M., et al. Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res 2010, 70(3):925-935.
45. Bencokova Z., Kaufmann M.R., Pires I.M., Lecane P.S., Giaccia A.J., Hammond E.M. ATM activation and signaling under hypoxic conditions. Mol Cell Biol 2009, 29(2):526-537.
46. Olcina M.M., Foskolou I.P., Anbalagan S., et al. Replication stress and chromatin context link ATM activation to a role in DNA replication. Mol Cell 2013, 52(5):758-766.
47. Reaper P.M., Griffiths M.R., Long J.M., et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 2011, 7(7):428-430.
48. Fokas E., Prevo R., Pollard J.R., et al. Targeting ATR invivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis 2012, 3:e441.
49. Peasland A., Wang L.Z., Rowling E., et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer 2011, 105(3):372-381.
50. Hammond E.M., Dorie M.J., Giaccia A.J. Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation. Cancer Res 2004, 64(18):6556-6562.
51. Pires I.M., Bencokova Z., McGurk C., Hammond E.M. Exposure to acute hypoxia induces a transient DNA damage response which includes Chk1 and TLK1. Cell Cycle 2010, 9(13):2502-2507.
52. Hasvold G., Nahse-Kumpf V., Tkacz-Stachowska K., Rofstad E.K., Syljuasen R.G. The efficacy of CHK1 inhibitors is not altered by hypoxia, but is enhanced after reoxygenation. Mol Cancer Ther 2013, 12(5):705-716.
53. Mitchell J.B., Choudhuri R., Fabre K., et al. Invitro and invivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010, 16(7):2076-2084.
54. Yang H., Yoon S.J., Jin J., et al. Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy. Biochem Biophys Res Commun 2011, 406(1):53-58.
55. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035):913-917.
56. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434(7035):917-921.
57. Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005, 5(9):689-698.
58. Chan N., Pires I.M., Bencokova Z., et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 2010, 70(20):8045-8054.
59. Albertella M.R., Loadman P.M., Jones P.H., et al. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res 2008, 14(4):1096-1104.
60. Evans J.W., Yudoh K., Delahoussaye Y.M., Brown J.M. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res 1998, 58(10):2098-2101.
61. Jameson M.B., Rischin D., Pegram M., et al. Aphase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol 2010, 65(4):791-801.
62. Wang J., Foehrenbacher A., Su J., et al. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia. Clin Cancer Res 2012, 18(6):1684-1695.
63. Cazares-Korner C., Pires I.M., Swallow I.D., et al. CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia/reoxygenation through inhibition of Chk1 and Aurora A. ACS Chem Biol 2013, 8(7):1451-1459.
64. Lindquist K.E., Cran J.D., Kordic K., et al. Selective radiosensitization of hypoxic cells using BCCA621C: a novel hypoxia activated prodrug targeting DNA-dependent protein kinase. Tumor Microenviron Ther 2013, 1:46-55.
65. Rischin D., Hicks R.J., Fisher R., et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. JClin Oncol 2006, 24(13):2098-2104.
66. Rischin D., Peters L.J., O'Sullivan B., et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. JClin Oncol 2010, 28(18):2989-2995.
67. Peters L.J., O'Sullivan B., Giralt J., et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. JClin Oncol 2010, 28(18):2996-3001.
68. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997, 38(2):285-289.
69. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996, 56(19):4509-4515.
70. Okunieff P., Hoeckel M., Dunphy E.P., Schlenger K., Knoop C., Vaupel P. Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys 1993, 26(4):631-636.
71. Gatenby R.A., Kessler H.B., Rosenblum J.S., et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988, 14(5):831-838.
72. Fyles A.W., Milosevic M., Pintilie M., Hill R.P. Cervix cancer oxygenation measured following external radiation therapy. Int J Radiat Oncol Biol Phys 1998, 42(4):751-753.
73. Nordsmark M., Overgaard J. Aconfirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000, 57(1):39-43.
74. Varia M.A., Calkins-Adams D.P., Rinker L.H., et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 1998, 71(2):270-277.
75. Janssens G.O., Rademakers S.E., Terhaard C.H., et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. JClin Oncol 2012, 30(15):1777-1783.
76. Airley R.E., Loncaster J., Raleigh J.A., et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 2003, 104(1):85-91.
77. Winter S.C., Buffa F.M., Silva P., et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 2007, 67(7):3441-3449.
78. Buffa F.M., Harris A.L., West C.M., Miller C.J. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 2010, 102(2):428-435.
79. Toustrup K., Sorensen B.S., Alsner J., Overgaard J. Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin Radiat Oncol 2012, 22(2):119-127.
80. Toustrup K., Sorensen B.S., Lassen P., Wiuf C., Alsner J., Overgaard J. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 2012, 102(1):122-129.
81. Overgaard J., Eriksen J.G., Nordsmark M., Alsner J., Horsman M.R. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005, 6(10):757-764.
82. Shao Q., Morgounova E., Jiang C., Choi J., Bischof J., Ashkenazi S. Invivo photoacoustic lifetime imaging of tumor hypoxia in small animals. JBiomed Opt 2013, 18(7):076019.
83. Chia K., Fleming I.N., Blower P.J. Hypoxia imaging with PET: which tracers and why?. Nucl Med Commun 2012, 33(3):217-222.
84. Dubois L.J., Lieuwes N.G., Janssen M.H., et al. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci USA 2011, 108(35):14620-14625.
85. Vavere A.L., Lewis J.S. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans 2007, 21(43):4893-4902.
86. Krohn K.A., Link J.M., Mason R.P. Molecular imaging of hypoxia. JNucl Med 2008, 49(Suppl. 2):129S-148S.
87. Burgman P., O'Donoghue J.A., Lewis J.S., Welch M.J., Humm J.L., Ling C.C. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol 2005, 32(6):623-630.
88. Laforest R., Dehdashti F., Lewis J.S., Schwarz S.W. Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging 2005, 32(7):764-770.
89. Mees G., Dierckx R., Vangestel C., Van de Wiele C. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 2009, 36(10):1674-1686.
90. Sorger D., Patt M., Kumar P., et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003, 30(3):317-326.
91. Piert M., Machulla H.J., Picchio M., et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. JNucl Med 2005, 46(1):106-113.
92. Gronroos T., Bentzen L., Marjamaki P., et al. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004, 31(4):513-520.
93. Chen L., Zhang Z., Kolb H.C., Walsh J.C., Zhang J., Guan Y. (1)(8)F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with (1)(8)F-FMISO. Nucl Med Commun 2012, 33(10):1096-1102.
94. Zegers C.M., van Elmpt W., Wierts R., et al. Hypoxia imagingwith [(18)F]HX4 PET in NSCLC patients: defining optimal imaging parameters. Radiother Oncol 2013, 109(1):58-64.
95. Abolmaali N., Haase R., Koch A., et al. Two or four hour [(1)(8)F]FMISO-PET in HNSCC. When is the contrast best?. Nuklearmedizin 2011, 50(1):22-27.
96. Okamoto S., Shiga T., Yasuda K., et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. JNucl Med 2013, 54(2):201-207.
97. Nehmeh S.A., Lee N.Y., Schroder H., et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008, 70(1):235-242.
98. Yuan H., Schroeder T., Bowsher J.E., Hedlund L.W., Wong T., Dewhirst M.W. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). JNucl Med 2006, 47(6):989-998.
99. Valtorta S., Belloli S., Sanvito F., et al. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer. JNucl Med 2013, 54(7):1106-1112.
100. Busk M., Munk O.L., Jakobsen S., et al. Assessing hypoxia in animal tumor models based on pharmacokinetic analysis of dynamic FAZA PET. Acta Oncol 2010, 49(7):922-933.
101. Thorwarth D., Eschmann S.M., Scheiderbauer J., Paulsen F., Alber M. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 2005, 5:152.
102. Koh W.J., Bergman K.S., Rasey J.S., et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995, 33(2):391-398.
103. Kikuchi M., Yamane T., Shinohara S., et al. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann Nucl Med 2011, 25(9):625-633.
104. Komar G., Seppanen M., Eskola O., et al. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. JNucl Med 2008, 49(12):1944-1951.
105. Horsman M.R., Mortensen L.S., Petersen J.B., Busk M., Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012, 9(12):674-687.
106. Le Q.T., Fisher R., Oliner K.S., et al. Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer. Clin Cancer Res 2012, 18(6):1798-1807.
107. Beck R., Roper B., Carlsen J.M., et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. JNucl Med 2007, 48(6):973-980.
108. Chitneni S.K., Bida G.T., Yuan H., et al. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model. JNucl Med 2013, 54(8):1339-1346.
109. O'Connor J.P., Jackson A., Parker G.J., Roberts C., Jayson G.C. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 2012, 9(3):167-177.
110. Halle C., Andersen E., Lando M., et al. Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI. Cancer Res 2012, 72(20):5285-5295.
111. Egeland T.A., Simonsen T.G., Gaustad J.V., Gulliksrud K., Ellingsen C., Rofstad E.K. Dynamic contrast-enhanced magnetic resonance imaging of tumors: preclinical validation of parametric images. Radiat Res 2009, 172(3):339-347.
112. Gulliksrud K., Mathiesen B., Galappathi K., Rofstad E.K. Quantitative assessment of hypoxia in melanoma xenografts by dynamic contrast-enhanced magnetic resonance imaging: intradermal versus intramuscular tumors. Radiother Oncol 2010, 97(2):233-238.
113. Donaldson S.B., Betts G., Bonington S.C., et al. Perfusion estimated with rapid dynamic contrast-enhanced magnetic resonance imaging correlates inversely with vascular endothelial growth factor expression and pimonidazole staining in head-and-neck cancer: a pilot study. Int J Radiat Oncol Biol Phys 2011, 81(4):1176-1183.
114. Ogawa S., Menon R.S., Tank D.W., et al. Functional brain mapping by blood oxygenation level-dependent contrast magnetic resonance imaging. A comparison of signal characteristics with a biophysical model. Biophys J 1993, 64(3):803-812.
115. Howe F.A., Robinson S.P., McIntyre D.J., Stubbs M., Griffiths J.R. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 2001, 14(7-8):497-506.
116. Baudelet C., Gallez B. How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors?. Magn Reson Med 2002, 48(6):980-986.
117. Griffiths J.R., Taylor N.J., Howe F.A., et al. The response of human tumors to carbogen breathing, monitored by Gradient-Recalled Echo Magnetic Resonance Imaging. Int J Radiat Oncol Biol Phys 1997, 39(3):697-701.
118. Hoskin P.J., Carnell D.M., Taylor N.J., et al. Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. Int J Radiat Oncol Biol Phys 2007, 68(4):1065-1071.
119. O'Connor J.P.B., Jackson A., Buonaccorsi G.A., et al. Organ-specific effects of oxygen and carbogen gas inhalation on tissue longitudinal relaxation times. Magn Reson Med 2007, 58(3):490-496.
120. Matsumoto K., Bernardo M., Subramanian S., et al. MR assessment of changes of tumor in response to hyperbaric oxygen treatment. Magn Reson Med 2006, 56(2):240-246.
121. Burrell J.S., Walker-Samuel S., Baker L.C., et al. Exploring DeltaR(2) * and DeltaR(1) as imaging biomarkers of tumor oxygenation. JMagn Reson Imaging 2013, 38(2):429-434.
122. Linnik I.V., Scott M.L.S., Holliday K., et al. Non-invasive tumor hypoxia measurement using magnetic resonance imaging in U87 murine model of human glioma and in patients with glioblastoma. Magn Reson Med 2013 Jun 24, [Epub ahead of print]. 10.1002/mrm.24826.
123. O'Connor J.P., Naish J.H., Parker G.J., et al. Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. Int J Radiat Oncol Biol Phys 2009, 75(4):1209-1215.